Sign Out
Hypersensitivity to doxorubicin or any other component of the product, other anthracyclines or anthracenediones.
Intravenous (IV) use: Persistent myelosuppression; Hepatic impairment; Myocardial insufficiency; Recent myocardial infarction; Severe arrythmias; Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones (see Precautions).
Safety in pregnancy and lactation has not been established.
Continue with Google